PO.MCB08.02 · 分子与细胞生物学
Y染色体改变的泛癌种图景
The pan-cancer landscape of chromosome Y alterations
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
背景:尽管在大多数非性别特异性癌症的发病率和死亡率方面存在充分记录的男性偏倚,Y染色体(chrY)仍是一个基因组盲区。包括癌症基因组图谱(TCGA)和PCAWG在内的主要泛癌种基因组联盟,由于与其单倍体状态、重复结构以及与X染色体同源性相关的计算挑战,历来将chrY排除在体细胞分析之外。因此,chrY改变的体细胞图景,包括Y完全缺失(LOY)、结构变异(SV)、单核苷酸变异(SNV)和插入缺失(INDEL),在很大程度上仍未被刻画。
方法:我们实施了一个泛癌种计算框架,利用来自对TCGA队列26种癌症类型全面重新分析的深度全基因组测序(WGS)数据。我们开发并应用了一个新型生物信息学流程,以准确检出体细胞LOY、复杂SV、SNV和INDEL。该流程专门设计用于克服chrY的分析挑战,包括其重复结构以及对假常染色体区域(PAR)的正确处理。通过变异支持度指标以及识别问题区域中的断点来标记潜在的假象。
结果:分析揭示了各肿瘤类型间高度异质的chrY改变图景。我们发现某些肿瘤类型中体细胞SV的高患病率,如膀胱癌(BLCA)、头颈部癌(HSNC)、胃癌(STAD)和前列腺癌(PRAD),而其他类型,如甲状腺癌(THCA)和肾透明细胞癌(KIRC),则很少受累。在受累肿瘤中,SV图景包括众多染色体间易位,这些易位常显示低变异等位基因频率(VAF),提示亚克隆起源。相比之下,chrY缺失的克隆性在不同癌症类型间有所不同。SNV/INDEL负荷在某些癌症中较为可观,例如在胶质母细胞瘤(GBM)和PRAD中,但集中于非编码区域,蛋白质编码突变较为少见。有趣的是,我们观察到在若干肿瘤类型中chrY的SNV谱富集了C>T和T>C替换。
结论:我们开发了一个计算框架来系统分析多种癌症类型中的Y染色体,克服了历史性的分析挑战。我们的结果揭示了包括结构变异和点突变在内的多样化体细胞改变谱。这些发现提供了首个全面的、泛癌种的体细胞chrY图景图。
查看英文原文 English abstract
Background : Despite the well-documented male bias in the incidence and mortality of most non-sex-specific cancers, the Y chromosome (chrY) remains as a genomic blind spot. Major pan-cancer genomic consortia, including The Cancer Genome Atlas (TCGA) and PCAWG, have historically excluded the chrY from somatic analyses due to computational challenges related to its haploid state, repetitive structure, and homology with the X chromosome. Consequently, the somatic landscape of chrY alterations, including complete loss of Y (LOY), structural variants (SVs), single-nucleotide variants (SNVs), and INDELs, remains largely uncharacterized.
Methods : We implemented a pan-cancer computational framework utilizing deep whole-genome sequencing (WGS) data from a comprehensive re-analysis of 26 cancer types from the TCGA cohort. We developed and applied a novel bioinformatic pipeline to accurately call somatic LOY, complex SVs, SNVs, and INDELs. The pipeline was specifically designed to overcome analytical challenges of the chrY, including its repetitive structure and the correct handling of pseudoautosomal regions (PARs). Potential artifacts were flagged using variant-support metrics and by identifying breakpoints in problematic regions.
Results : The analysis revealed a highly heterogeneous landscape of chrY alterations across tumor types. We found a high prevalence of somatic SVs in some tumor types, such as bladder (BLCA), head and neck (HSNC), stomach (STAD), and prostate (PRAD) cancers, while others, like thyroid (THCA) and renal clear cell carcinoma (KIRC), were rarely affected. In affected tumors, the SV landscape included numerous inter-chromosomal translocations, which often showed low variant allele frequency (VAF), suggesting a subclonal origin. In contrast, the clonality of chrY deletions varied across cancer types. The SNV/INDEL burden was substantial in certain cancers, for example, in glioblastoma (GBM) and PRAD, but was concentrated in non-coding regions, with protein-coding mutations being infrequent. Interestingly, we observed a chrY SNV spectrum enriched in C>T and T>C substitutions across several tumor types.
Conclusion : We developed a computational framework to systematically analyze the Y chromosome across multiple cancer types, overcoming historical analytical challenges. Our results reveal a diverse spectrum of somatic alterations, including structural variants and point mutations. These findings provide the first comprehensive, pan-cancer map of the somatic chrY landscape.
利益披露 Disclosure
L. Corchete Sanchez, None.
C. Bao,
Inocras Inc. Employment.
S. Belkin, None.
A. D. Cherniack,
Bayer ).
B. P. Danysh, None..
Z. Everton, None..
D. I. Heiman, None.
R. Kim,
Inocras Inc. Employment.
A. Kowalewski, None.
G. Lee,
Inocras Inc. Employment.
W. Lee,
Inocras Inc. Employment.
D. Lehotzky, None..
X. Loinaz, None..
V. Narasimha Swamy, None.
H. Park,
Inocras Inc. Employment.
R. Solan, None..
C. Stewart, None..
H. Tomono, None..
S. Van Seters, None..
G. Wang, None..
S. Wiseman, None.
Y. Ju,
Inocras Inc. Employment.
G. Getz,
IBM ).
Pharmacyclics/Abbvie ).
Bayer ).
Genentech ).
Calico ).
Ultima Genomics ).
Inocras ).
Google ).
Kite ).
Novartis ).
Scorpion Therapeutics Independent Contractor, Stock, Other Business Ownership.
Predicta Biosciences Stock, Other Business Ownership.
Antares Therapeutics Stock.
E. Rheinbay,
Inocras Inc. ).